Earlier this month, Novo predicted that its sales would decline by between 5% and 13% in 2026 amid rising competition.
Author: J. Edward Moreno
Source: Sherwood News.
Novo Nordisk sinks after its experimental obesity drug falls short of Eli Lilly’s in head-to-head trial